Upper Macungie planners endorse Lilly's Lehigh Valley manufacturing campus

Planning officials in Upper Macungie Township, Pennsylvania, recommended final approval on August 19, 2026, for Eli Lilly's proposed manufacturing campus, known as Project Kennedy ^[1][2]. The $3.5 billion facility would sit on about 150 acres near Fogelsville, west of Allentown, close to Interstate 78 ^[1][2]. Township review continued afterward, with officials still weighing construction traffic and worker transportation plans ^[1][2].

The planned campus totals 797,432 square feet and will be built in phases, starting with an amenities building and visitor center in the site's southwest section ^[1][2]. Lilly told planners it closed on the property last month and that the site will run on a mix of above-ground and below-ground utilities, eventually operating three shifts of eight to 12 hours each ^[1]. Company representatives said the facility will not use chemicals covered under federal Chemical Facility Anti-Terrorism Standards ^[1][2].

The work at the site will focus on final assembly rather than making active drug ingredients from scratch. Officials said the plant will combine externally manufactured pharmaceutical ingredients into solutions and prepare injectable medicines for retail packaging ^[1][2]. One source reports the facility is expected to handle Zepbound, Lilly's tirzepatide weight-loss injection, along with retatrutide, a next-generation drug still in clinical trials ^[2]. Construction is expected to run through 2029, with manufacturing operations projected to begin in 2031 ^[2].

The project is expected to generate about 2,000 construction jobs over its buildout, with roughly 1,200 construction workers and 300 administrative employees using rented parking on Tilghman Street and shuttle buses to reach the site ^[1][2]. Truck traffic is projected at about 45 trucks a day, or roughly 90 trips, with 64 of those trips expected during peak hours ^[1][2]. The completed campus will have an eight-foot perimeter fence, transitioning from an architectural design along Main Street to chain-link along Interstate 78, plus 24/7 security with card access and a visitor screening center ^[1][2].

Why it matters for patients

This is a construction and zoning story, not a medical one, but it points to where future supply of injectable GLP-1 and related drugs could come from. If the plant proceeds as described, it would add US-based final-assembly and packaging capacity for injectable medicines tied to Lilly's portfolio, including Zepbound ^[2]. One source also links the campus to retatrutide, an experimental drug still in clinical trials that is not yet approved for sale ^[2]. Patients should not expect any near-term change in supply or price from this announcement: manufacturing operations are not projected to begin until 2031, with construction running through 2029 ^[2]. Local approval processes like this one are also not final purchase or regulatory decisions; they concern land use, traffic and worker logistics, not drug approval ^[1][2].

What happens next

Township review of the plan continued past the August 19 planning commission recommendation, with further discussion of construction traffic and worker transportation logistics ^[1][2]. Construction on the campus is expected to continue through 2029, and manufacturing operations are projected to start in 2031 ^[2]. The sources do not specify a date for final township approval beyond the planning commission's recommendation, and it is not yet known from these sources whether additional local votes or permits remain before construction begins.